

### *Amendments to the Specification*

#### *I. In the Title*

Please substitute the pending Title of the Invention with the following Title of the Invention:

~~SUPPLEMENTED AND UNSUPPLEMENTED TISSUE SEALANTS,~~  
~~METHODS OF THEIR PRODUCTION AND USE~~ SUPPLEMENTED FIBRIN  
MATRIX DELIVERY SYSTEMS

#### *II. In the Specification*

Please substitute the pending paragraph starting at page 25 of the instant specification with the following paragraph:

Fig. 1 shows Figs. 1A-1F show Western blots of gels on which samples containing HBGF-1 $\beta$  had been incubated with 250 ~~[[U/ml]]~~ units/ml (U/ml) thrombin in the presence of increasing concentrations of heparin. Solutions containing HBGF-1 $\beta$  (10 $\mu$ g/ml), thrombin (250  $\mu$ g/ml), and increasing concentrations of heparin (0, 0.5, 5, 10, 20 and 50 units/ml) were incubated at 37°C for 72 hours. Aliquots were periodically removed from each of the incubating mixtures and were loaded onto 8% SDS polyacrylamide gels that were prepared and run as described by Laemmli (*Nature* 227:680 (1970)). The gel was then electroblotted onto nitrocellulose and the band corresponding to HBGF-1 $\beta$  was identified using an affinity-purified polyclonal rabbit antiserum to HBGF-1 $\beta$ .

The concentrations of heparin in the incubating mixtures were: panel A) 0 ~~units/ml (U/ml)~~; panel B) 0.5 U/ml ~~[[u/ml]]~~; Panel C) 5 U/ml; panel D) 10 U/ml; panel E) 20 U/ml; and panel F) 50 U/ml. In the gels pictured in each of panels A F, each lane

contains the following: lane 1 contains SDS-PAGE low molecular weight standards; lane 2 contains biotinylated standards; lane 3 contains 10 µg/ml HBGF-1β; lane 4 contains 250 U/ml thrombin; and lanes 5-13 contain samples removed from the incubating mixtures at times 0, 1, 2, 4, 6, 8, 24, 48, and 72 hours.

Please substitute the pending paragraph starting at page 26, line 12 of the specification with the following paragraph:

Fig. 2 shows the incorporation of 3H-thymidine as a function of relative HBGF-1β concentration. Samples of the HBGF-1β were incubated, as described in Figure 1 and Example 2, in the presence of 250 U/ml thrombin and 5 U/ml heparin for 0, 24 or 72 hours. Dilutions of these samples were then added to NIH 3T3 cells, which were plated as described in Example 3. CPM is plotted v. HBGF-1β concentration.